- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

NICE guidance recommends Bayer’s chronic kidney disease treatment

The National Institute for Health and Care Excellence (NICE) has published new guidance
recommending the use of Kerendia®(finerenone) by NHS England as an option for treating chronic kidney disease (CKD) (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.

Finerenone is recommended as an add-on to optimised standard care, which should include, unless they are unsuitable, the highest tolerated licensed doses of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and sodium–glucose cotransporter-2 (SGLT2) inhibitors, for people who have an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 or more.1

Dr Kieran McCafferty, Consultant Nephrologist Barts Health NHS Trust, said: “People with chronic kidney disease associated with type 2 diabetes have significant risk of progression to kidney failure or premature death, particularly due to increased risk of cardiovascular disease compared with people with CKD alone. There has long been an unmet need for additional treatment options for people with CKD associated with T2D, especially as the residual risk of kidney disease progression and cardiovascular events remains high despite current therapies.1 The NICE recommendation of finerenone is therefore very welcome news and provides physicians with an important add-on option for protecting our patients by delaying kidney disease progression.”

Dr Raj Thakkar, GP, Present Elect and CKD Lead, Primary Care Cardiovascular Society (PCCS), said: “Chronic kidney disease is one of the most common and burdensome complications of high-risk conditions including diabetes and hypertension.5 Without early identification and optimisation of treatment, CKD progresses over time leading to accelerated adverse renal and cardiovascular outcomes including end-stage kidney disease and coronary disease, heart failure, valve disease, stroke, and peripheral vascular disease. Building on the NICE guidance, the PCCS is developing a quality improvement programme to support colleagues to systematically and proactively identify and manage CKD in the primary care setting.”

Dr Antonio Payano, Senior Bayer Representative, Head of Pharmaceuticals at Bayer UK & Ireland said: “We are thrilled that finerenone is now made available to eligible adults in England who live with chronic kidney disease associated with type 2 diabetes, a condition that is associated with poor health outcomes for patients and high expenditure to the NHS services when managing the end-stage complications of CKD. We will continue to support the NHS and healthcare professionals to bring this treatment option to benefit more patients. Given the rising prevalence of T2D, we are fully committed to raising awareness of CKD among T2D patients and working with physicians on CKD knowledge sharing to help improve diagnosis and empower patients for better outcomes.”

References

1 Finerenone for treating chronic kidney disease in people with type 2 diabetes. NICE Technology Appraisal Guidance [TA877]. Available at: https://www.nice.org.uk/guidance/ta877.

2 NICE Final Appraisal Document. Finerenone for treating chronic kidney disease in type 2 diabetes. Available at: https://www.nice.org.uk/guidance/gid-ta10820/documents/final-appraisal-determination-document Last accessed: March 2023.

3 Bakris G et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England      Journal of Medicine. 2020. 383, 2219-2229.

4 Filippatos G, et al. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. Circulation 2021. 143:540–552.

5 Erfanpoor S et al. Diabetes, Hypertension, and Incidence of Chronic Kidney Disease: Is There any Multiplicative or Additive Interaction? Int J Endocrinol Metab. 2021 January; 19(1):e101061.

- Advertisement -
Emma Cooper
Emma Cooper
Emma is Content Manager at Pf Media.

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription